<DOC>
	<DOCNO>NCT01612468</DOCNO>
	<brief_summary>A randomised , double-blind , placebo control study effect liraglutide additional treatment insulin HbA1c , body weight hypoglycaemia poorly regulate type 1 diabetes patient . Background : Treatment glucagon-like peptid 1 ( GLP-1 ) agonists liraglutide exanatide lead weight loss decrease haemoglobin A1c oral anti diabetic treat type 2 diabetes patient . It estimate 40-50 % type 1 diabetes patient US suffers overweight poor glycaemic control ( HbA1c &gt; 8 % ) . Small study , placebo control , report effect add liraglutide group well regulate ( HbA1c &lt; 7.5 % ) normal overweight insulin treat type 1 diabetes patient 24 week . A decrease HbA1c , weight , insulin dos glycaemic excursion measure continuous glucose monitoring see . Primary objective : To investigate effect liraglutide 1.8 mg daily compare placebo 24 week change HbA1c patient type 1 diabetes add-on therapy insulin . Secondary objective : To investigate effect liraglutide add-on therapy insulin compare placebo change : Weight , insulin dose , hypoglycaemic event , CGM , BMI , body composition , quality life , treatment satisfaction , food preference , meal test , CIMT , PWV 24 hour blood pressure .</brief_summary>
	<brief_title>Liraglutide Type 1 Diabetes</brief_title>
	<detailed_description>A randomised , double-blind , placebo control study effect liraglutide additional treatment insulin HbA1c , body weight hypoglycaemia poorly regulate type 1 diabetes patient . Background Treatment glucagon-like peptid 1 ( GLP-1 ) agonists liraglutide exenatide lead weight loss decrease haemoglobin A1c ( HbA1c ) oral anti diabetic treat type 2 diabetes patient . Smaller study show similar effect insulin treat type 2 diabetes patient , increase risk hypoglycaemia . It estimate 40-50 % type 1 diabetes patient US suffers overweight poor glycaemic control ( HbA1c &gt; 8 % ) . At present treatment type 1 diabetes solely consist insulin injection . A recent study report effect add liraglutide group well regulate ( HbA1c &lt; 7.5 % ) normal overweight insulin treat type 1 diabetes patient 24 week . A decrease HbA1c , weight , insulin dos glycaemic excursion measure continuous glucose monitoring see . The study placebo control . The available literature suggest GLP-1 agonist reduce insulin dose weight well regulate type 1 diabetes patient , normal- overweight . To knowledge , study address whether liraglutide improve HbA1c reduce bodyweight overweight poorly regulate type 1 diabetes patient . At present efficient way reduce HbA1c use insulin pump therapy , study suggest decrease HbA1c approximately 0.5 % . Insulin pump therapy however option compliant patient . In clinic treat type 1 diabetes 40-50 % patient HbA1c &gt; 8 % many patient , due insufficient compliance , candidate insulin pump . At Steno Diabetes Center approximately 3000 well characterize type 1 diabetes patient follow outpatient clinic , 40-50 % HbA1c &gt; 8.0 % . If liraglutide give daily result reduction HbA1c 0.5 % probably cost-effective additional therapy type 1 diabetes patient insufficient metabolic control . Several study show liraglutide lower systolic blood pressure . Dysregulation increase risk microvascular complication type 1 diabetes microalbuminuria result need treatment antihypertensive medication . Overweight increase risk hypertension arteriosclerosis thereby cardiovascular disease . Carotis intima medium thickness validate estimate future cardiovascular disease pulse wave velocity measure arterial stiffness . We perform 24 hour blood pressure measurement document possible effect liraglutide blood pressure CIMT PWV investigate effect liraglutide cardiovascular disease arteriosclerosis .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Overweight</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<criteria>Type 1 diabetes accord WHO criteria ≥ 1 year Age ≥ 18 year BMI &gt; 25 kg/m2 HbA1c &gt; 8.0 % visit 0 Insulin pump treatment Hypoglycaemia unawareness ( unability register low blood glucose ) Diabetic gastroparesis Compromised kidney function ( eGFR &lt; 60 ml/min/1,73m2 ) , dialysis kidney transplantation visit 0 Liver disease elevate plasma alanine aminotransferase ( ALT ) &gt; three time upper limit normal ( measured visit 0 possibility one repeat analysis within week , last measure value conclusive ) Acute chronic pancreatitis Inflammatory bowel disease Cancer unless complete remission &gt; 5 year History thyroid adenoma carcinoma Other concomitant disease treatment accord investigator 's assessment make patient unsuitable study participation Alcohol/drug abuse Fertile woman use contraceptive Pregnant nursing woman Known suspected hypersensitivity trial product relate product Receipt investigational drug within 30 day prior visit 0 Simultaneous participation clinical intervention trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Diabetes</keyword>
	<keyword>Liraglutide</keyword>
	<keyword>Hypoglycaemia</keyword>
	<keyword>Hyperglycaemia</keyword>
	<keyword>CIMT</keyword>
	<keyword>PWV</keyword>
	<keyword>Food preference</keyword>
	<keyword>Blood pressure</keyword>
</DOC>